Radiologia Brasileira - Publicação Científica Oficial do Colégio Brasileiro de Radiologia

INTRODUCTION

Complex collections typically present a therapeutic challenge and can range from organized collections of blood with locoregional compressive symptoms to infectious processes that, in patients with various comorbidities, can result in unfavorable clinical outcomes such as sepsis and death⁽¹⁾.

Complicated infection is a major cause of high morbidity and mortality, occurring most commonly in the abdominal cavity—in approximately 30% of cases⁽¹⁾—and thoracic cavity—in 18–60%⁽²⁾. Among the main factors associated with a worse prognosis are worsening of severe underlying diseases, failure to determine the etiology of the collection, the use of inappropriate empirical antibiotic therapy, and infections caused by multidrug-resistant organisms. Early diagnosis, as well as the introduction of aggressive clinical and surgical therapies, are key to achieving favorable clinical outcomes⁽¹⁾.

Minimally invasive percutaneous drainage guided by imaging, such as ultrasound and tomography, which are frequently used in conjunction⁽³⁾, is a well-established therapeutic option in the approach to collections at various sites, such as subcutaneous collections, as well as those in the intramuscular compartment, abdomen/pelvic cavity, and thorax^(3–6).

The advent of imaging equipment that provide better definition and various types of drains (to deal with superficial and deep collections of different viscosities) have resulted in an increase in the number of cases in which the minimally invasive technique is indicated, as well as improving outcomes. However, in thick, septated, encapsulated collections of blood containing debris, the minimally invasive approach provides less than satisfactory results^(7–9). In this context, the injection of fibrinolytic agents into the collection, in order to reduce the viscosity of the contents and facilitate the flow through the lumina of drainage tubes of different calibers^(10,11), represents a solution for the treatment of these less common cases in which the success of minimally invasive drainage is limited^(8,9,12), precluding the need for a more aggressive surgical approach, which is sometimes not applicable in patients who are more seriously ill.

The objective of this study was to analyze the safety and efficacy of recombinant tissue plasminogen activator (r-TPA) injection in the evolution of imaging-guided percutaneous drainage of thick fluid collections. We also describe the initial experience of the interventional radiology department of our hospital in the application of the technique.


MATERIALS AND METHODS

This was a single-center study involving the retrospective analysis of patients submitted to percutaneous drainage of thick superficial or intracavitary fluid collections, followed by injection of a fibrinolytic agent, between April 2011 and May 2015. This study was approved by the medical ethics committee of the institution.

Administration of r-TPA

The decision to use the fibrinolytic agent was made jointly between the interventional radiology team and the members of the clinical-surgical treatment team assigned to the patient.

After the appropriate positioning of the percutaneous drain had been verified by imaging, the fibrinolytic agent was injected through the lumen of the drain. The r-TPA was diluted in saline solution (ranging from 10 mL to 40 mL depending on the estimated initial volume of the collection) and instilled within the collection, with subsequent closure of the drain for 1 h. Subsequently, the drain was opened and the flow rate was measured, the measurement excluding the volume of solution administered. The treatment cycle consisted of administration of a daily dose of the saline-r-TPA solution for three consecutive days, unless the collection resolved spontaneously before that period. During administration of the fibrinolytic agent, the serum fibrinogen level was monitored and a coagulation test was performed.


RESULTS

Percutaneous drainage of superficial or intracavitary collections, with r-TPA injection, was performed 53 times in 51 patients, two patients undergoing drainage of two different collections each. Of the 51 patients, 30 (58.8%) were women. The mean age of the patients was 55.6 years (range, 17–93 years).

Abdominal and pelvic collections were the most common (n = 38; 73%), followed by thoracic collections (n = 8; 15%) and collections in soft tissue (n = 7; 12%). The predominant cause of the collections was postoperative complications (n = 35; 66%), followed by pneumonia evolving to empyema (n = 8), liver abscess (n = 2), trauma (n = 2), complicated pancreatitis (n = 1), pyelonephritis (n = 1), renal cyst rupture (n = 1), loculated ascites associated with carcinomatosis (n = 1), and hematoma of the abdominal wall.

Drainage was performed with general anesthesia in 25 (49%) of the patients (n = 25), local anesthesia in 18 (35%), and local anesthesia combined with intravenous sedation in 8 (16%). Among the imaging methods used in order to guide the drainage, ultrasound alone was used in 27 (51%) of the procedures, computed tomography alone was used in 8 (15%), and the combination of the two methods was used in 18 (34%).

A total of 61 drains were used in order to access the 53 collections (45 were accessed with a single drain and 8 were accessed with two drains per collection). Of the 61 drains, 52 (85%) were large-caliber drains (12–16 Fr) and 9 (15%) were smaller-caliber drains (4–10 Fr).

The saline-r-TPA solution was administered after the correct positioning of the drain had been confirmed, being injected immediately after drainage in 28 (53%) of the cases, with a mean interval between the initial drainage and the r-TPA injection of 2.7 ± 4 days (range, 0–13 days).

The mean daily dose of r-TPA was 5.7 ± 3.0 mg/collection (range 2–10 mg), with a mean treatment duration of 2.6 days. The mean time between r-TPA injection and drain withdrawal was 7.7 days. There were no changes seen on the coagulation tests evaluated during the study.

Among the collections treated with r-TPA injection, the overall success rate of percutaneous drainage in conjunction with the use of a fibrinolytic agent was 96%, successful drainage being achieved in 51 cases, with the following distribution (Figures 1 and 2): after one r-TPA cycle, in 45 cases (85%); after two r-TPA cycles, with resolution of the collection after the second cycle, in 1 (2%); and after placement of a second percutaneous drain in 5 (9%).




There were no cases of recurrence of the collection after drain removal. Percutaneous drainage was ineffective, making it necessary to drain the collection surgically, in only 2 cases (4%). In those cases, the percutaneous drain was removed during the surgical procedure. The only complication observed was bleeding in the collection bed, which occurred in one case, after the third day of the r-TPA cycle, in a collection secondary to early colorectal anastomosis fistula. The bleeding occurred in a patient with normal coagulation test results and was resolved through coil-spring embolization. No side effects or complications were observed during or after administration of the fibrinolytic agent in the other patients.


DISCUSSION

Imaging-guided percutaneous drainage presents a high level of safety, with low rates of morbidity and mortality, whether performed with the Seldinger technique (using a guidewire) or with the tandem trocar technique (direct drainage of the collection, without the use of a guidewire), resulting in early recovery of patients in the post-procedure period⁽¹³⁾.

Despite the small number of studies on the injection of fibrinolytic agents into thick or loculated collections, some authors suggest that the injection of such agents increases the efficacy of percutaneous drainage of abscess, thus improving clinical outcomes⁽⁵⁾. Most such studies have involved the administration of urokinase or streptokinase^{(3,6,7,11,14–16)}, although a few have used r-TPA ^(5,17).

Our results demonstrate that the use of r-TPA in thick or septated collections, at a low single daily dose (mean, 5.7 mg) for up to three days, improved the evolution at different drainage sites, with a percutaneous drainage success rate of 96%. Froudarakis et al.⁽¹⁸⁾, in their sample of 20 patients, reported a 95% success rate in drainage of thoracic empyemas using a single daily dose of 25 mg of r-TPA for three days. Among the complications described, 25% of the patients presented pain during the administration of the fibrinolytic agent and 15% evolved to intrathoracic hemorrhage. Gervais et al.⁽¹⁷⁾ reported a success rate of 86% for drainage of intrathoracic collections with administration of low doses of r-TPA (4–6 mg), compared with the 73% success rate reported by Cheng et al.⁽¹⁹⁾ in patients with abdominal collections receiving r-TPA at doses of 2–4 mg. In both of those studies, the r-TPA was administered in three-day cycles, although it was injected twice daily. These results indicate that the technique is safer when lower doses (≤ 10 mg) are administered.

Lahorra et al.⁽²⁰⁾ demonstrated the safety of the use of a fibrinolytic agent in intracavitary abscesses, reporting no changes in the coagulation test results. The patient in our sample who developed bleeding did not present systemic alterations on the coagulation tests. After a multidisciplinary discussion, it was decided that the bleeding could be attributed to the local effects of the fibrinolytic agent in the region of the collection, due to the fact that it is a friable area in the early postoperative period.

The major limitation of our study was its retrospective design, which precluded standardization of the r-TPA dose according to the volume of the collection.


CONCLUSION

The use of a single low daily dose of r-TPA for up to three consecutive days, as a therapeutic adjunct to the percutaneous drainage of thick or loculated collections, proved to be a safe and effective technique that should be considered for inclusion in the minimally invasive arsenal for use in selected situations.


REFERENCES

1. Sartelli M. A focus on intra-abdominal infections. World J Emerg Surg. 2010;5:9.

2. Marks DJB, Fisk MD, Koo CY, et al. Thoracic empyema: a 12-year study from a UK tertiary cardiothoracic referral centre. PLoS One. 2012;7: e30074.

3. Laborda A, De Gregorio MA, Miguelena JM, et al. Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial. Eur Radiol. 2009;19:1772–9.

4. Berná-Serna JD, Berná-Mestre JD, Galindo PJ, et al. Use of urokinase in percutaneous drainage of large breast abscesses. J Ultrasound Med. 2009;28:449–54.

5. Beland MD, Gervais DA, Levis DA, et al. Complex abdominal and pelvic abscesses: efficacy of adjunctive tissue-type plasminogen activator for drainage. Radiology. 2008;247:567–73.

6. Jerjes-Sánchez C, Ramirez-Rivera A, Elizalde JJ, et al. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial. Chest. 1996;109:1514–9.

7. Haaga JR, Nakamoto D, Stellato T, et al. Intracavitary urokinase for enhancement of percutaneous abscess drainage: phase II trial. AJR Am J Roentgenol. 2000;174:1681–5.

8. Sahn SA. Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas. Thorax. 1998;53 Suppl 2:S65–72.

9. Moulton JS, Benkert RE, Weisiger KH, et al. Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase. Chest. 1995;108:1252–9.

10. Shenoy-Bhangle AS, Gervais DA. Use of fibrinolytics in abdominal and pleural collections. Semin Intervent Radiol. 2012;29:264–9.

11. Bouros D, Schiza S, Panagou P, et al. Role of streptokinase in the treatment of acute loculated parapneumonic pleural effusions and empyema. Thorax. 1994;49:852–5.

12. Light RW. A new classification of parapneumonic effusions and empyema. Chest. 1995;108:299–301.

13. Maher MM, Gervais DA, Kalra MK, et al. The inaccessible or undrainable abscess: how to drain it. Radiographics. 2004;24:717–35.

14. Kornecki A, Sivan Y. Treatment of loculated pleural effusion with intrapleural urokinase in children. J Pediatr Surg. 1997;32:1473–5.

15. Cases Viedma E, Lorenzo Dus MJ, González-Molina A, et al. A study of loculated tuberculous pleural effusions treated with intrapleural urokinase. Respir Med. 2006;100:2037–42.

16. Park CS, Chung WM, Lim MK, et al. Transcatheter instillation of urokinase into loculated pleural effusion: analysis of treatment effect. AJR Am J Roentgenol. 1996;167:649–52.

17. Gervais DA, Levis DA, Hahn PF, et al. Adjunctive intrapleural tissue plasminogen activator administered via chest tubes placed with imaging guidance: effectiveness and risk for hemorrhage. Radiology. 2008;246:956–63.

18. Froudarakis ME, Kouliatsis G, Steiropoulos P, et al. Recombinant tissue plasminogen activator in the treatment of pleural infections in adults. Respir Med. 2008;102:1694–700.

19. Cheng D, Nagata KT, Yoon HC. Randomized prospective comparison of alteplase versus saline solution for the percutaneous treatment of loculated abdominopelvic abscesses. J Vasc Interv Radiol. 2008;19:906–11.

20. Lahorra JM, Haaga JR, Stellato T, et al. Safety of intracavitary urokinase with percutaneous abscess drainage. AJR Am J Roentgenol. 1993;160:171–4.










MD, Physician in the Department of Interventional Radiology of the Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

Study conducted in the Department of Interventional Radiology of the Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.

Mailing address:
Dra. Priscila Mina Falsarella
Hospital Israelita Albert Einstein – Departamento de Radiologia Intervencionista
Avenida Albert Einstein, 627, Morumbi
São Paulo, SP, Brazil, 05652-900
E-mail: primina@gmail.com

Received May 19, 2017
Accepted after revision July 3, 2017